Invention Grant
- Patent Title: Mutant endoglycoceramidases with enhanced synthetic activity
-
Application No.: US14754310Application Date: 2015-06-29
-
Publication No.: US10294504B2Publication Date: 2019-05-21
- Inventor: Karl F. Johnson , Shawn Defrees , Stephen Withers , Mark Vaughan
- Applicant: La Jolla Pharmaceutical Company , The University of British Columbia
- Applicant Address: US CA San Diego CA Vancouver
- Assignee: La Jolla Pharmaceutical Company,The University of British Columbia
- Current Assignee: La Jolla Pharmaceutical Company,The University of British Columbia
- Current Assignee Address: US CA San Diego CA Vancouver
- Agency: Foley Hoag LLP
- Agent David P. Halstead; Lucas P. Watkins
- Main IPC: C12N9/24
- IPC: C12N9/24 ; C12P19/26

Abstract:
The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.
Public/Granted literature
- US20160032342A1 Mutant Endoglycoceramidases with Enhanced Synthetic Activity Public/Granted day:2016-02-04
Information query